1. MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE. (June 2017) Authors: Pott, C.; Belada, D.; Danesi, N.; Fingerle‐Rowson, G.R.; Gribben, J.; Harbron, C.G.; Hoster, E.; Kahl, B.S.; Kehden, B.; Mundt, K.E.; Nicolas‐Virelizier, E.; Sehn, L.H.; Cheson, B.D. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗